# Nuclide record evergreen-theragnostics (company). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/companies/evergreen-theragnostics/>
  a schema:Organization ;
  nuclide:kind "company" ;
  schema:identifier "evergreen-theragnostics" ;
  schema:name "Evergreen Theragnostics"@en ;
  schema:description "Evergreen Theragnostics manufactures radioactive cancer medicines for other companies and develops its own imaging agent for neuroendocrine tumours and a treatment for small cell lung cancer. Lantheus agreed to buy it in 2025."@en ;
  schema:url <https://nuclide.cc/companies/evergreen-theragnostics/>, <https://www.evergreentgn.com/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.evergreentgn.com/>, <https://www.evergreentgn.com/2025/01/28/lantheus-to-acquire-evergreen-theragnostics-for-upfront-payment-of-250-million-to-drive-strategic-evolution-into-fully-integrated-radiopharmaceutical-leader/>, <https://www.evergreentgn.com/news/> ;
  schema:addressCountry "US" ;
  nuclide:related <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:indications <https://nuclide.cc/indications/neuroendocrine/>, <https://nuclide.cc/indications/sclc/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/pet/> .